These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 26057975)

  • 1. Access to new technologies in multipatented vaccines: challenges for Brazil.
    Possas C; de Souza Antunes AM; Mendes FM; de Oliveira Rodrigues Schumacher S; Martins RM; Homma A
    Nat Biotechnol; 2015 Jun; 33(6):599-603. PubMed ID: 26057975
    [No Abstract]   [Full Text] [Related]  

  • 2. Health-care patents and interests of patients.
    Luthra R
    Bull World Health Organ; 2006 Nov; 84(11):919. PubMed ID: 17143470
    [No Abstract]   [Full Text] [Related]  

  • 3. Patents & public health: international trade obligations and domestic policy development.
    Amani B
    Health Law Can; 2002 Feb; 22(3):76-84. PubMed ID: 11915591
    [No Abstract]   [Full Text] [Related]  

  • 4. International patent law-boon or bane of biotech?
    Basu P
    Nat Biotechnol; 2005 Jan; 23(1):13-5. PubMed ID: 15637604
    [No Abstract]   [Full Text] [Related]  

  • 5. TRIPS post-2005 and access to new antiretroviral treatments in southern countries: issues and challenges.
    Orsi F; D'Almeida C; Hasenclever L; Camara M; Tigre P; Coriat B
    AIDS; 2007 Oct; 21(15):1997-2003. PubMed ID: 17885289
    [No Abstract]   [Full Text] [Related]  

  • 6. Intellectual property and access to ART: unwise choice of terminology.
    Stallman R
    PLoS Med; 2006 Nov; 3(11):e509; author reply e510. PubMed ID: 17132062
    [No Abstract]   [Full Text] [Related]  

  • 7. Intellectual property rights, the World Trade Organization and public health: the Brazilian perspective.
    Viana JM
    Conn J Int Law; 2002; 17(2):311-8. PubMed ID: 12688298
    [No Abstract]   [Full Text] [Related]  

  • 8. [Patentability of living material: public health concerns (1/2)].
    Manuel C; Hairion D; Antoniotti S; Lafon C; Siméoni MC; Auquier P
    Presse Med; 2002 Oct; 31(34):1591-5. PubMed ID: 12426975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asserting the primacy of health over patent rights: a comparative study of the processes that led to the use of compulsory licensing in Thailand and Brazil.
    Rosenberg ST
    Dev World Bioeth; 2014 Aug; 14(2):83-91. PubMed ID: 24750542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Public access versus proprietary rights in genomic information: what is the proper role of intellectual property rights?
    Mueller JM
    J Health Care Law Policy; 2003; 6(2):222-40. PubMed ID: 15017961
    [No Abstract]   [Full Text] [Related]  

  • 11. What next for a COVID-19 intellectual property waiver?
    Zarocostas J
    Lancet; 2021 May; 397(10288):1871-1872. PubMed ID: 34022975
    [No Abstract]   [Full Text] [Related]  

  • 12. US trade rules seek to balance health and patent protection.
    Wadman M; Cherry M
    Nature; 1999 Dec; 402(6762):567-8. PubMed ID: 10604448
    [No Abstract]   [Full Text] [Related]  

  • 13. Intellectual property rights and challenges for development of affordable human papillomavirus, rotavirus and pneumococcal vaccines: Patent landscaping and perspectives of developing country vaccine manufacturers.
    Chandrasekharan S; Amin T; Kim J; Furrer E; Matterson AC; Schwalbe N; Nguyen A
    Vaccine; 2015 Nov; 33(46):6366-70. PubMed ID: 26368398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Should ANVISA be permitted to reject pharmaceutical patent applications in Brazil?
    Mueller LL; Taketsuma Costa SM
    Expert Opin Ther Pat; 2014 Jan; 24(1):1-4. PubMed ID: 24206261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Access to vaccine technologies in developing countries: Brazil and India.
    Milstien JB; Gaulé P; Kaddar M
    Vaccine; 2007 Nov; 25(44):7610-9. PubMed ID: 17913312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The scope of utility in the twenty-first century: new guidance for gene-related patents.
    Summers TM
    Georgetown Law J; 2003 Jan; 91(2):475-509. PubMed ID: 15046071
    [No Abstract]   [Full Text] [Related]  

  • 17. Designing an optimal intellectual property system for plants: a US Supreme Court debate.
    Janis MD; Kesan JP
    Nat Biotechnol; 2001 Oct; 19(10):981-3. PubMed ID: 11581668
    [No Abstract]   [Full Text] [Related]  

  • 18. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
    't Hoen E
    Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
    [No Abstract]   [Full Text] [Related]  

  • 19. Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?
    Oliveira MA; Bermudez JA; Chaves GC; Velásquez G
    Bull World Health Organ; 2004 Nov; 82(11):815-21. PubMed ID: 15640916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intellectual property and products of nature.
    Sagoff M
    Am J Bioeth; 2002; 2(3):12-3. PubMed ID: 12230841
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.